Ph3 study of Rilvegostomig + Bevacizumab with/without Tremelimumab 1L Tx in HCC (ARTEMIDE-HCC01)
Phase III Clinical Trial
A Phase III Randomized Open-label Sponsor-blinded Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01/D7029C00001)